Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Beckmann

Showing results (731-740 of 1,041) with videos related to

Pageof 105
Sort By:
Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.
Plos One|January 14, 2012
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detectionMichael G Schrauder, Reiner Strick, Rüdiger Schulz-Wendtland, et al.
Breast Cancer Research : BCR|January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markersLothar Häberle, Ramona Erber, Paul Gass, et al.
Reproductive Biomedicine Online|December 5, 2017
Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissueMatthias W Beckmann, Ralf Dittrich, Laura Lotz, et al.
Precision Clinical Medicine|January 22, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impactHanna Huebner, Pauline Wimberger, Elena Laakmann, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2014
Percent Mammographic Density and Dense Area as Risk Factors for Breast CancerC Rauh, C C Hack, L Häberle, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
HLA|August 5, 2024
Validation and functional follow-up of cervical cancer risk variants at the HLA locusRieke Eisenblätter, Finja Seifert, Peter Schürmann, et al.
Breast Cancer Research and Treatment|November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyNadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Pageof 105

Showing results (731-740 of 1,041) with videos related to

Sort By:
Pageof 105
Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.
Plos One|January 14, 2012
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detectionMichael G Schrauder, Reiner Strick, Rüdiger Schulz-Wendtland, et al.
Breast Cancer Research : BCR|January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markersLothar Häberle, Ramona Erber, Paul Gass, et al.
Reproductive Biomedicine Online|December 5, 2017
Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissueMatthias W Beckmann, Ralf Dittrich, Laura Lotz, et al.
Precision Clinical Medicine|January 22, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impactHanna Huebner, Pauline Wimberger, Elena Laakmann, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2014
Percent Mammographic Density and Dense Area as Risk Factors for Breast CancerC Rauh, C C Hack, L Häberle, et al.
Breast Cancer Research and Treatment|July 6, 2012
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerMartin Schuler, Ahmad Awada, Philipp Harter, et al.
HLA|August 5, 2024
Validation and functional follow-up of cervical cancer risk variants at the HLA locusRieke Eisenblätter, Finja Seifert, Peter Schürmann, et al.
Breast Cancer Research and Treatment|November 1, 2016
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyNadia Harbeck, Steffen Saupe, Elke Jäger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Pageof 105